Financials data is unavailable for this security.
View more
Year on year Aquestive Therapeutics Inc grew revenues 6.09% from 47.68m to 50.58m while net income improved from a loss of 54.41m to a smaller loss of 7.87m.
| Gross margin | 69.39% |
|---|---|
| Net profit margin | -59.75% |
| Operating margin | -37.58% |
| Return on assets | -41.55% |
|---|---|
| Return on equity | -- |
| Return on investment | -54.06% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Aquestive Therapeutics Inc fell by 3.40m. Cash Flow from Financing totalled 3.97m or 7.86% of revenues. In addition the company used 6.38m for operations while cash used for investing totalled 995.00k.
| Cash flow per share | -0.4236 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.4982 |
|---|---|
| Tangible book value per share | -0.4982 |
More ▼
Balance sheet in USDView more
| Current ratio | 6.37 |
|---|---|
| Quick ratio | 5.91 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
